Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Regardless of the initial treatment
2025-01-09
Regardless of the initial treatment, most patients with advanced NSCLC experience relapse and disease progression [15]. A subpopulation of immediate concern and clinical need is patients who have advanced NSCLC that is especially aggressive, which is usually defined as disease that rapidly progresse
-
Mouse M-CSF ligand Due to anatomical and physiologic charact
2025-01-09
Due to anatomical and physiologic characteristics of the eye, administration of ophthalmic medicines is difficult and many studies showed that only approximately 5% of the administrated dose are absorbed by intraocular tissues, making the treatment unfeasible for diseases located in posterior segmen
-
br Under normal physiological conditions the agonist binds t
2025-01-09
Under normal physiological conditions, the agonist binds to AT1R on the surface of the plasma membrane and activates the receptor, mediating downstream signaling. Then, activated AT1R is phosphorylated by protein kinase C (PKC) [13] or G protein coupled receptor kinases (GPKs, such as GRK2 [13], G
-
Clinical observations of individuals with a decrease in LOX
2025-01-09
Clinical observations of individuals with a decrease in 12-LOX ddhUTP are consistent with 12-LOX potentiating platelet activation and thrombus formation [40]. However, the relative contribution of 12-LOX to these complex disorders cannot be fully elucidated in the absence of a biochemical assessment
-
br Author Contributions br Acknowledgments
2025-01-09
Author Contributions Acknowledgments Introduction Cerebral ischemia-reperfusion (I/R) injury is a pathological phenomenon that occurs after restoration of blood supply to vivit tissues subsequent to ischemia or hypoxia (Carden and Granger, 2000). It typically occurs after therapeutic throm
-
In hypothalamus as indicated in Fig
2025-01-09
In hypothalamus, as indicated in Fig. 2 (column A) and following the enzymatic cascade represented in Fig. 1, we could hypothesize a predominance of Ang 2–10 and Ang III formation in SHR compared to WKY. This is in agreement with previous results that reported significant higher rate of Ang 2–10 for
-
br cDNA cloning gene structure and chromosomal localization
2025-01-09
cDNA cloning, gene structure and chromosomal localization The cDNA for the leukocyte-type 12S-lipoxygenase was first cloned from porcine leukocytes [9], and later from mouse [10], [11], rat [12], [13], bovine [14] and rabbit [15] sources. The cDNA for the platelet-type 12S-lipoxygenase cDNA has b
-
br Materials and Methods br Results In the Base Analysis
2025-01-09
Materials and Methods Results In the Base Analysis (53% of patients having access to the ALK test in both Current and Alternative Scenarios), a total of 16,583 patients were tested of whom 1,252 were assumed to be ALK-positive. A more extensive use of Ventana in the Alternative Scenario determ
-
An alternative approach to the
2025-01-08
An alternative approach to the administration of ADO agonists is to amplify the actions of endogenous ADO by inhibiting the ADO-metabolizing enzyme, ADO kinase (AK). Inhibition of AK has the net effect of potentiating the local concentration and the effects of ADO in the extracellular compartment. T
-
Finasteride has been shown to be a
2025-01-08
Finasteride has been shown to be a mechanism-based inhibitor of 5AR-2 [9]. Finasteride acts as an alternate substrate for 5AR-2 and is initially bound in an extremely stable enzyme-bound NADP-dihydrofinasteride adduct which is ultimately processed to dihydrofinasteride. The NADP-dihydrofinasteride a
-
br Results br Discussion ER and GR play opposite
2025-01-08
Results Discussion ER and GR play opposite phenotypic roles in the normal endometrium, with ER promoting growth and GR inhibiting growth. Here, we show that in endometrial cancer, GR expression is associated with worse outcomes and higher-grade tumors, and this association is observed only in
-
br Current limitations and future
2025-01-08
Current limitations and future directions There are several limitations associated with PET imaging of aromatase using carbon-11 labeled aromatase inhibitors. Due to the very short half-life of carbon 11 (20min), PET studies with currently available, validated tracers can only be performed in med
-
KIN-193 There are several AP binding sites in the sequence
2025-01-08
There are several AP-1 KIN-193 in the sequence of TIMP-1 promoter [18,19]. EBV could up-regulate TIMP-1 expression by binding to the AP-1 site in the TIMP-1 promoter [18]. IL-32, a newly multi-function cytokine, could activate AP-1, NF-κβ, p38MAPK signal pathways, and induce cytokine expressions, su
-
The proposed method was also used
2025-01-07
The proposed method was also used to evaluate resistance to natamycin (a natural antibiotic produced by Streptomyces natalensis used for fungal control on cheese surface) of 9 fungi, including those previously mentioned as well as Phoma pinodella UBOCC-A-116004, Candida parapsilosis UBOCC-A-216002,
-
The Nagoya Heart Study enrolled patients with hypertension a
2025-01-07
The Nagoya Heart Study enrolled patients with hypertension and type 2 diabetes or impaired ll 37 tolerance (12). Patients were randomized to valsartan- or amlodipine-based regimens with a BP target of ≤130/80 mmHg. The primary outcome was a composite of sudden cardiac death, myocardial infarction,
15460 records 26/1031 page Previous Next First page 上5页 2627282930 下5页 Last page